Biotech Showcase 2019: Stem Cell Approach Shows Promise In Neurodegeneration
Executive Summary
Recent studies have shown that mesenchymal stem cells (MSCs) hold great potential as a cell‐based therapy for a number of neurodegenerative diseases. Speaking on the sidelines of Biotech Showcase 2019, Chaim Lebovitz, President and CEO of Brainstorm Cell Therapeutics, tells Scrip how the New York-based biotech is currently enrolling a multi-dose, double-blind, placebo-controlled Phase III study of its MSC therapy, leveraging the company’s NurOwn platform, in 200 rapid-progressing amyotrophic lateral sclerosis patients.